OrthoPediatrics Corp generated $70.5 million in revenue for the second quarter, marking a 15% increase year-over-year. This growth reflects the company’s strong market position in pediatric orthopedics and encourages investor confidence in its updated annual revenue guidance of $265 million to $269 million.
Key Highlights
- OrthoPediatrics Corp (NASDAQ: KIDS) posted a remarkable Q2 2026 revenue of $70.5 million, representing a solid 15% increase from $61.1 million in the same quarter last year.
- OrthoPediatrics achieved total revenue of $70.5 million in Q2 2026, the highest in its history.
- The company reported record adjusted EBITDA of $6.8 million, up from $4.1 million in the previous year, showcasing improved profitability metrics that appeal to investors.
OrthoPediatrics Corp (NASDAQ: KIDS) posted a remarkable Q2 2026 revenue of $70.5 million, representing a solid 15% increase from $61.1 million in the same quarter last year. This performance surpassed analysts' expectations, as the company reported a loss per share of $-0.26, better than the consensus estimate of $-0.31. Investors may find the higher-than-expected revenue and the strategic growth outlook particularly compelling as they consider the company’s next steps.
Record Revenue Milestone
OrthoPediatrics achieved total revenue of $70.5 million in Q2 2026, the highest in its history. This figure represents a 14% increase in domestic revenue, which reached $54.8 million, while international revenue surged 22% to hit $15.7 million. This growth is primarily attributed to the rising demand for trauma and deformity products, with a remarkable 26% increase in that segment alone.
This strong revenue growth positions OrthoPediatrics favorably, reflecting a strong market demand that could lead to sustained momentum in the coming months. The company's commitment to pediatric orthopedic innovations illustrates its potential long-term value for investors.
Profitability Gains
The company reported record adjusted EBITDA of $6.8 million, up from $4.1 million in the previous year, showcasing improved profitability metrics that appeal to investors. Gross profit margin also edged up to 74%, compared to 72% last year. Despite a net loss of $7.2 million, the reduction in free cash flow usage by 78% to $3.1 million signals enhanced cash management strategies.
With growing revenues and tightening costs, management's focus on innovation is expected to drive further efficiency, reinforcing its leadership position in the industry. Such performance metrics can foster investor confidence, especially as the company aims for cash-flow breakeven by year-end.
Increased Revenue Guidance
This represents anticipated growth of 12% to 14% compared to 2025. The company's strong Q2 results, combined with the announcement of an exclusive distribution agreement with OSSIO, set the stage for sustained growth in pediatric orthopedic solutions. The upward revision in guidance indicates management's confidence in capitalizing on recent momentum, suggesting to investors that upward trajectory may continue.
All eyes are now on the company’s August 4 conference call, where further insights are likely to be shared.
Conference Call Ahead
The event will provide an opportunity for management to discuss the implications of their record revenue and improved profitability metrics. Investors may be particularly keen to understand how the upcoming innovation cycle and market strategies will enhance the firm’s foothold in pediatric medicine. The insights garnered from this conference could significantly influence market sentiment moving forward.
Peers Moving on This News
- Neogen Corp (NEOG) little changed
- STAAR Surgical Co (STAA) up 1.1%
- Bioventus Inc (BVS) up 1.3%
Analysis based on the Form 8-K filed 4 August 2026; figures verified against the filing and live market data.
This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.






Please wait processing your request...